Exploring Novel TYK2-Targeted Therapies for Plaque Psoriasis

Linda Stein Gold, MD, and Bruce Strober, MD, PhD, assess the efficacy of traditional and newer treatment options for psoriasis. They also discuss therapeutic targets and the goals of therapy.

Thought leaders talk about the approval and integration of a first-in-class agent into the treatment armamentarium. They also review the mechanisms of TYK2 inhibition.

Linda Stein Gold, MD, and Bruce Strober, MD, PhD, explore the phase 3 data for deucravacitinib, as well as the dosage, and lack of drug-drug interactions associated with it.

Linda Stein Gold, MD, and Bruce Strober, MD, PhD, place the safety data for deucravacitinib in clinical context.

Thought leaders talk about blood monitoring protocols with deucravacitinib.

Linda Stein Gold, MD, and Bruce Strober, MD, PhD, discuss the nuances of treatment selection for patients with moderate to severe plaque psoriasis.

Linda Stein Gold, MD, and Bruce Strober, MD, PhD, share considerations for ensuring that patients on Medicare and Medicaid receive the appropriate medication.

Linda Stein Gold, MD, and Bruce Strober, MD, PhD, discuss the potential use of TYK2 inhibitors in combination with other modalities.

Linda Stein Gold, MD, and Bruce Strober, MD, PhD, review the clinical and practical impact of TYK2 inhibition and its evolving role within the treatment landscape for psoriatic disease.